In 1993, my father died of lung cancer in India. During the years I watched him suffer with the disease, I decided that I would join pharmaceutical industry after my PhD to develop drugs (particularly aimed at treating cancer) and help improve the lives of patients.
Mohan Bangalore
Senior Director and Site Head, Wyeth
In 1993, my father died of lung cancer in India. During the years I watched him suffer with the disease, I decided that I would join pharmaceutical industry after my PhD to develop drugs (particularly aimed at treating cancer) and help improve the lives of patients. While at GlaxoSmithKline, I helped set up oncology clinical trials in India and China for Tykerb (lapatinib), which is now on the market for treatment of breast cancer. It was gratifying to see the drug I worked on help cancer patients. That moment was decisive, as it exemplifies our ability to improve patients' lives. The experience also opened the door for me to India and China clinical operations.
My major accomplishment at Wyeth has been the establishment of the India Clinical Research Center (ICRC) in Bangalore, through a novel partnership with Accenture. Today, ICRC has some 160 team members supporting core clinical functions such as clinical writing, statistical programming, medical research support, document quality, document technology, and clinical administrative data support. I also provide administrative and operational oversight for ICRC, and identify opportunities across functions and develop strategic solutions with stakeholders.
I look forward to developing new outsourcing models and creating innovative ways for sponsors and service providers to collaborate. One thing I know is that I will continue to make significant contributions to global clinical operations in the pharmaceutical industry. I see myself becoming an industry leader in clinical outsourcing with a special focus on India and China clinical operations.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.